

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (update)

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

Several stakeholders raised a point that the recommendation to use European Respiratory Society (ERS) 1993 reference values for spirometry was out of date. These reference values were accompanied by a warning that they may lead to under-diagnosis in older people and are not applicable in black and Asian populations, as they were estimated based solely on data from a European population. The committee agreed with the stakeholders that it was appropriate to update this to refer to the GLI 2012 reference values, which have been developed using data from a wider pool of ethnicities (Caucasians, African-Americans, North East Asians and South East Asians). However, the committee included an acknowledgement that these reference values are not applicable to all ethnic groups.

No other new equality issues were raised during consultation. Other equality issues were raised, but these had been discussed prior to consultation and are covered in the sections above.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Some recommendations have changed post-consultation, but none of these changes should make it more difficult in practice for a specific group to access services compared with other groups.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Some recommendations have changed post-consultation, but none of these changes should have an adverse impact on people with disabilities because of something that is a consequence of the disability.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.1, 4.2 and 4.3, or otherwise fulfil NICE's obligations to advance equality?

Some recommendations have changed post-consultation, but none of these changes necessitate additional recommendations or explanations as they are not expected to introduce any additional barriers or difficulties with access to services.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

The Committee's considerations of equality issues are described in the evidence reviews for each question, in particular in the benefits and harms, and other considerations sections of the discussion sections associated with the relevant review questions.

Updated by Developer: Susan Spiers

Date: 11.9.18

Approved by NICE quality assurance lead: Simon Ellis

Date: 05. 12. 18

5.0 After Guidance Executive amendments – if applicable (to be completed by appropriate NICE staff member after Guidance Executive)

5.1 Outline amendments agreed by Guidance Executive below, if applicable:

NICE's Guidance Executive requested that recommendation 1.1.14, which is aimed at non-smokers, be amended to align with recommendation 1.1.13 for smokers by noting that emphysema is an independent risk factor for lung cancer. It was agreed that the population covered by recommendation 1.1.14 would include ex-smokers and therefore alignment of the recommendations for this was appropriate.

Approved by Developer: Sue Spiers

Date 15 November 2018

Approved by NICE quality assurance lead: Simon Ellis

Date: 05.12.18

